News
About the PCSK9 Education and Research Forum
PCSK9 Education and Research Forum is the independent resource on PCSK9 science and its translation into critically important new treatments to lower low density lipoprotein cholesterol (LDL-C), which promise to transform the prognosis of millions of patients with hypercholesterolaemia (cholesterol disorders), accelerated atherosclerotic vascular heart disease and a high risk of premature cardiovascular (CV) death and disability.Aims & ObjectivesMission StatementEditorial BoardPartnership & OutreachForthcoming Meetings
Question of the Month
Will evinacumab eliminate the need for LDL-apheresis in patients with homozygous FH?
Professor Derick Raal (University of the Witwatersrand, Johannesburg, South Africa) gives his view.
Find out more »Download Now: New Slide Deck Programme
Previous slide decks focused on landmark studies which used a monoclonal antibody approach to inhibit PCSK9. The next in this series discusses inclisiran, a small interfering RNA therapy, which prevents production of PCSK9 at its primary source in the liver.
Find out more »
News from the Trials
Keep up to date with latest news and analyses from PCSK9 inhibitor trials.
- ORION-8: Evaluating long-term dosing with inclisiran in high-risk patients
- NCT03409744: Longer-term data with evinacumab in homozygous FH
- FOURIER: Benefit with evolocumab across all vascular territories
Trial Resources
For expert analysis and insights
Hot Topics
15th Virtual Closed Scientific Expert Meeting of the Editorial Board
Keynote lectures from the experts
Prof Nabil Seidah overviews the history of PCSK9 science, and discusses how it might play a role in viral infections and cancer.
Prof Peter Libby discusses the critical question: How does LDL lowering stabilize vulnerable plaques?
From the Editors
Proof-of-concept: Gene-editing for PCSK9 inhibition
Prof. John Chapman, Pitié-Salpêtrière University Hospital, Sorbonne University, and National Institute for Health and Medical Research (INSERM), Paris, France.
Other related reports:
DA-VINCI: Need to do better with LDL cholesterol management in practice in Europe
Pooled analysis highlights the promise of inclisiran
Inclisiran: Update on efficacy, dosing regimen, safety and COVT trial
Very low lipoprotein(a) and very low LDL cholesterol – are they safe?
Latest Views
Meet our Editorial Board
View all our Editorial Board
Prof John ChapmanResearch Professor at the University of Pierre and Marie Curie
Prof Henry GinsbergDirector, Irving Institute for Clinical and Translational Research
Dr Michel FarnierClinician based at Point Medical, Dijon, France
Prof Frederick RaalDirector, Carbohydrate & Lipid Metabolism Research Unit
Prof Anthony WierzbickiConsultant in Metabolic Medicine/Chemical Pathology
